Literature DB >> 8016773

Eosinophilic activation in cystic fibrosis.

D Y Koller1, M Götz, I Eichler, R Urbanek.   

Abstract

BACKGROUND: The neutrophil is a potent contributor to pulmonary destruction in cystic fibrosis. Since eosinophils also possess destructive potential the involvement of eosinophils in cystic fibrosis has been investigated.
METHODS: Eosinophil numbers and levels of eosinophil cationic protein (ECP), a marker of eosinophil activation, were determined in the serum of 42 patients with cystic fibrosis and in the sputum of 10 of them. To determine neutrophil activation levels of myeloperoxidase (MPO) were also measured.
RESULTS: In cystic fibrosis increased serum levels of ECP were detected compared with healthy non-atopic subjects. Serum ECP levels were not related to the peripheral blood eosinophil count. A strong correlation with ECP concentrations in sputum indicated that the level of ECP in serum was representative of its pulmonary level. Levels of MPO were also increased in cystic fibrosis. A strong correlation was found between MPO and pulmonary function. In addition, ECP was related to arterial oxygen and carbon dioxide tensions. Antibiotic treatment reduced neutrophil activation without effect on ECP levels.
CONCLUSIONS: Until now Pseudomonas aeruginosa and neutrophils were held to be primarily responsible for progressive tissue damage in cystic fibrosis. The results of this study suggest that eosinophils might also participate in such pulmonary destruction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8016773      PMCID: PMC474873          DOI: 10.1136/thx.49.5.496

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  20 in total

1.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors:  H SHWACHMAN; L L KULCZYCKI
Journal:  AMA J Dis Child       Date:  1958-07

2.  Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis.

Authors:  W Goldstein; G Döring
Journal:  Am Rev Respir Dis       Date:  1986-07

Review 3.  The eosinophilic leukocyte: structure and function.

Authors:  G J Gleich; C R Adolphson
Journal:  Adv Immunol       Date:  1986       Impact factor: 3.543

4.  Cytotoxic effects of the guinea pig eosinophil major basic protein on tracheal epithelium.

Authors:  E Frigas; D A Loegering; G J Gleich
Journal:  Lab Invest       Date:  1980-01       Impact factor: 5.662

5.  The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups.

Authors:  C W Bedrossian; S D Greenberg; D B Singer; J J Hansen; H S Rosenberg
Journal:  Hum Pathol       Date:  1976-03       Impact factor: 3.466

6.  Purification and cytotoxic potential of myeloperoxidase in cystic fibrosis sputum.

Authors:  J R Mohammed; B S Mohammed; L J Pawluk; D M Bucci; N R Baker; W B Davis
Journal:  J Lab Clin Med       Date:  1988-12

7.  Serum and plasma myeloperoxidase, elastase and lactoferrin content in acute myeloid leukaemia.

Authors:  I Olsson; T Olofsson; K Ohlsson; A Gustavsson
Journal:  Scand J Haematol       Date:  1979-05

8.  Broxaterol (Z.1170), a new oral beta 2-agonist compared with salbutamol.

Authors:  A P Perruchoud; H Bründler; R Godly; E Imhof; H Herzog
Journal:  Respiration       Date:  1987       Impact factor: 3.580

9.  The effect of purified human eosinophil major basic protein on mammalian ciliary activity.

Authors:  A T Hastie; D A Loegering; G J Gleich; F Kueppers
Journal:  Am Rev Respir Dis       Date:  1987-04

10.  Low levels of eosinophil cationic proteins in patients with asthma.

Authors:  P Venge; O Zetterström; R Dahl; L E Roxin; I Olsson
Journal:  Lancet       Date:  1977-08-20       Impact factor: 79.321

View more
  16 in total

1.  Relationship between disease severity and inflammatory markers in cystic fibrosis.

Authors:  D Y Koller; M Götz; C Wojnarowski; I Eichler
Journal:  Arch Dis Child       Date:  1996-12       Impact factor: 3.791

Review 2.  Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.

Authors:  Laurent Meijer; Deborah J Nelson; Vladimir Riazanski; Aida G Gabdoulkhakova; Geneviève Hery-Arnaud; Rozenn Le Berre; Nadège Loaëc; Nassima Oumata; Hervé Galons; Emmanuel Nowak; Laetitia Gueganton; Guillaume Dorothée; Michaela Prochazkova; Bradford Hall; Ashok B Kulkarni; Robert D Gray; Adriano G Rossi; Véronique Witko-Sarsat; Caroline Norez; Frédéric Becq; Denis Ravel; Dominique Mottier; Gilles Rault
Journal:  J Innate Immun       Date:  2016-03-18       Impact factor: 7.349

3.  Intestinal inflammation in cystic fibrosis.

Authors:  R L Smyth; N M Croft; U O'Hea; T G Marshall; A Ferguson
Journal:  Arch Dis Child       Date:  2000-05       Impact factor: 3.791

4.  Blockade of equilibrative nucleoside transporter 1/2 protects against Pseudomonas aeruginosa-induced acute lung injury and NLRP3 inflammasome activation.

Authors:  Eboni D Chambers; Alexis White; Alexander Vang; Zhengke Wang; Alfred Ayala; Tingting Weng; Michael Blackburn; Gaurav Choudhary; Sharon Rounds; Qing Lu
Journal:  FASEB J       Date:  2019-12-02       Impact factor: 5.191

Review 5.  Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.

Authors:  Sabina Schmitt-Grohé; Stefan Zielen
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

6.  Intrapulmonary concentrations of inflammatory cytokines in a mouse model of chronic respiratory infection caused by Pseudomonas aeruginosa.

Authors:  K Yanagihara; K Tomono; M Kuroki; Y Kaneko; T Sawai; H Ohno; Y Miyazaki; Y Higashiyama; S Maesaki; J Kadota; S Kohno
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

7.  Evidence for eosinophil activation in bronchiectasis unrelated to cystic fibrosis and bronchopulmonary aspergillosis: discrepancy between blood eosinophil counts and serum eosinophil cationic protein levels.

Authors:  C Kroegel; M Schüler; M Förster; R Braun; P R Grahmann
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

8.  Clinical value of monitoring eosinophil activity in asthma.

Authors:  D Y Koller; Y Herouy; M Götz; E Hagel; R Urbanek; I Eichler
Journal:  Arch Dis Child       Date:  1995-11       Impact factor: 3.791

9.  L'inflammation dans la Mucoviscidose.

Authors: 
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

10.  Inflammation in cystic fibrosis.

Authors: 
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.